The purpose of this study is to determine whether the treatment of patients with HFmrEF and
HFpEF at high risk of cardiovascular events with the mineralocorticoid receptor antagonist
(MRA) spironolactone reduces a composite of recurrent heart failure hospitalizations and
cardiovascular mortality.
Phase:
Phase 3
Details
Lead Sponsor:
Charite University, Berlin, Germany
Collaborators:
Coordinating Centre for Clinical Trials, Charité Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK) Echo Core Lab Berlin Institute for Cardiovascular Computer-assisted Medicine, Charité Ludwig-Maximilians - University of Munich University Medicine Greifswald University of Göttingen